This role is considered Hybrid.

The Medical Director, Early Assets will report to the Executive Director Early Assets and will be responsible for developing, leading, and executing the medical strategy and scientific engagement for multiple early-stage clinical programs, including assets being developed for hypertension, Alzheimer’s disease, Cardiometabolic disease, bleeding disorders and NASH. The successful candidate will serve as the primary point of contact for Clinical Development, New Product Commercialization and Global Commercial and Market Access teams and ensure that the Medical Affairs perspective and the voice of the patient and health care provider are incorporated into early development and commercialization strategies. This is a critical role in driving medical strategy and execution excellence, enabling commercial growth objectives through evidence generation, thought leadership, scientific engagement and product expertise.

Key Responsibilities

Provide strategic and scientific leadership to and define global Medical Affairs strategy for early-stage clinical programs.
Serve as a key member of the product development teams and meaningfully impact clinical development plans, study design, and data interpretation.
Lead and execute global scientific engagement strategy and drive excellence in scientific engagement with all key stakeholders.
Develop, initiate, and maintain strong relationships with international scientific leaders and key stakeholders to enhance awareness of Alnylam’s early asset portfolio.
Organize and manage global expert events (advisory boards, expert panels, symposia). Functions as the scientific medical expert internally and externally with national and international stakeholders.
Serves as a collaborator and key stakeholder in global clinical operations, global commercial development, global market access, global clinical R&D, global pharmacovigilance, and the promotion review committee (PRC) on medical aspects of the company’s products.
Provide strategic medical insights into R&D and commercialization strategies including profiling patient pathways, mapping the treatment landscape, and understanding prescriber patterns and dynamics.
Serve as the Medical Affairs lead for strategic partnerships:
- Partner with Value & Evidence Strategy team to develop and execute against integrated evidence generation plans
- Partner with the Medical Communications team to ensure the development of global communication, strategy, and execution of timely and high-quality communication of scientific data (publication and medical congress)
- Partner with Medical Training team to develop and deliver high quality scientific and skill-based training to medical team across regions
- Partner with Omnichannel team to a develop a strong Omnichannel prelaunch strategy for successful commercial launch.
Liaise with global and regional Medical Affairs to ensure medical insights from all key markets are integrated into and inform product development.
Represent Medical Affairs at appropriate leadership and development forums.
Oversees development and execution of comprehensive integrated evidence generation plans (IEGP)s ensuring high-quality publications from all types of evidence throughout development, launch, and in-market for all Alnylam pipeline and inline products.
Provides medical expertise and input into TA strategies ensuring close collaboration with R&D to deliver data and a label to support the Target Product Profile (TPP)s and reflect the value required to enable speedy patient access.

Qualifications

MD, DO, PhD, Pharm D or equivalent ex-US medical degree 5+ years of demonstrated high-level professional knowledge and skills in Medical Affairs and R&D, especially familiarity with early clinical development, in the pharmaceutical or biotech industry.
Deep therapeutic area knowledge and experience in Cardiometabolic and neurology Diseases preferred.
Extensive knowledge of the latest regulatory, policy, and technology developments preferred.
Experience in global scientific engagement strategy including scientific congresses, external experts and panels, symposia, etc, preferred.
Influential matrix leader who builds relationships across stakeholder types
Leadership presence with the ability to communicate complex data persuasively and relate study results and knowledge of therapeutic area to industry-specific applications Experience with RWE, diagnostics, translational work, and digital innovations.
Demonstrated expertise in informing R&D and commercialization strategies including patient pathways and mapping treatment landscape.
Preferred experience in working with Clinical development team and help shape CDP, data interpretation and dissemination.
Experience supporting due diligence for Business Development and serving as a medical expert for integrated asset planning, and building medical assessment framework.
High degree of professionalism, maturity, and confidentiality.
Strong written and verbal communication skills as well as strong leadership and interpersonal skills.
Demonstrated reputation as a well-respected, dynamic team player-coach.
Ability to deliver on company global program goals and objectives as they pertain to Medical Affairs.
Ability to influence positive organizational change at the company and team levels

About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.

Our culture: Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we’ve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK – among others.

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law.

Alnylam Pharmaceuticals

New Jobs

Global Medical Director